Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Johnson and Johnson
McKinsey
Dow

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ODM-201

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug ODM-201?

ODM-201 is an investigational drug.

There have been 42 clinical trials for ODM-201. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and University of Nottingham.

There are eight US patents protecting this investigational drug and eighty-three international patents.

Recent Clinical Trials for ODM-201
TitleSponsorPhase
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)Sir Mortimer B. Davis - Jewish General HospitalPhase 2
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerBayerPhase 2
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerProstate Cancer CanadaPhase 2

See all ODM-201 clinical trials

Clinical Trial Summary for ODM-201

Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201

See all ODM-201 clinical trials

US Patents for ODM-201

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ODM-201   Start Trial Carboxamide derivative and its diastereomers in stable crystalline form Orlon Corporation (Espoo, FI)   Start Trial
ODM-201   Start Trial Androgen receptor modulating compounds ORION CORPORATION (Espoo, FI)   Start Trial
ODM-201   Start Trial Process for the preparation of androgen receptor antagonists and intermediates thereof Orion Corporation (Espoo, FI)   Start Trial
ODM-201   Start Trial Carboxamide derivative and its diastereomers in stable crystalline form Orion Corporation (Espoo, FI)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ODM-201

Drugname Country Document Number Estimated Expiration Related US Patent
ODM-201 European Patent Office 3250554 2035-01-30   Start Trial
ODM-201 Japan 2018503662 2035-01-30   Start Trial
ODM-201 World Intellectual Property Organization (WIPO) 2016120530 2035-01-30   Start Trial
ODM-201 Argentina 078793 2029-10-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
McKinsey
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.